Total Payments
$2,667
2024 Payments
$815.72
Companies
38
Transactions
168
Medicare Patients
35,447
Medicare Billing
$15.5M
Payment Breakdown by Category
Food & Beverage$2,562 (96.1%)
Education$105.16 (3.9%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,562 | 161 | 96.1% |
| Education | $105.16 | 7 | 3.9% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $501.40 | 32 | $0 (2024) |
| Merck Sharp & Dohme LLC | $228.15 | 18 | $0 (2023) |
| PFIZER INC. | $224.76 | 15 | $0 (2024) |
| Amgen Inc. | $175.30 | 14 | $0 (2019) |
| Celgene Corporation | $151.66 | 8 | $0 (2024) |
| Janssen Biotech, Inc. | $130.88 | 7 | $0 (2024) |
| Daiichi Sankyo Inc. | $128.35 | 7 | $0 (2024) |
| Genentech USA, Inc. | $123.84 | 8 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $115.79 | 9 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $74.78 | 4 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $815.72 | 43 | Novartis Pharmaceuticals Corporation ($173.61) |
| 2023 | $509.06 | 26 | PFIZER INC. ($95.12) |
| 2022 | $47.04 | 3 | AstraZeneca Pharmaceuticals LP ($22.08) |
| 2021 | $45.93 | 3 | AstraZeneca Pharmaceuticals LP ($19.01) |
| 2020 | $38.70 | 2 | Exelixis Inc. ($22.60) |
| 2019 | $402.83 | 28 | Amgen Inc. ($138.32) |
| 2018 | $184.24 | 13 | Merck Sharp & Dohme Corporation ($39.83) |
| 2017 | $623.30 | 50 | Novartis Pharmaceuticals Corporation ($256.08) |
All Payment Transactions
168 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $15.98 | General |
| Category: ONCOLOGY | ||||||
| 12/04/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $24.95 | General |
| Category: Oncology | ||||||
| 11/25/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $11.54 | General |
| Category: ONCOLOGY | ||||||
| 11/07/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $29.09 | General |
| Category: Oncology | ||||||
| 10/29/2024 | Celgene Corporation | — | Food and Beverage | Cash or cash equivalent | $20.51 | General |
| 10/17/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $19.48 | General |
| Category: BioOncology | ||||||
| 10/02/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Oncology | ||||||
| 10/01/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $20.75 | General |
| Category: Hematology | ||||||
| 09/26/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $26.48 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological), TALVEY, DARZALEX | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: Oncology | ||||||
| 09/12/2024 | Janssen Biotech, Inc. | DARZALEX (Biological) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: Oncology | ||||||
| 09/10/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $31.58 | General |
| Category: Oncology | ||||||
| 09/05/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.78 | General |
| Category: Hematology | ||||||
| 08/22/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $24.25 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.10 | General |
| Category: ONCOLOGY | ||||||
| 08/21/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $18.50 | General |
| Category: Oncology | ||||||
| 08/08/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $16.63 | General |
| Category: Oncology | ||||||
| 08/06/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $20.09 | General |
| Category: ONCOLOGY | ||||||
| 07/23/2024 | ABBVIE INC. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2024 | E.R. Squibb & Sons, L.L.C. | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $14.87 | General |
| Category: Oncology | ||||||
| 06/25/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $21.40 | General |
| Category: Oncology | ||||||
| 06/19/2024 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $6.60 | General |
| Category: ONCOLOGY | ||||||
| 06/18/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $16.81 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 96 | 9,012 | 230,674 | $15.0M | $4.0M |
| 2022 | 100 | 9,424 | 236,499 | $13.2M | $3.5M |
| 2021 | 100 | 9,431 | 375,134 | $17.9M | $4.9M |
| 2020 | 97 | 7,580 | 204,414 | $11.0M | $3.1M |
Total Patients
35,447
Total Services
1,046,721
Medicare Billing
$15.5M
Procedure Codes
393
All Medicare Procedures & Services
393 procedure records from CMS Medicare Utilization — Page 1 of 16
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 41 | 28,200 | $3.1M | $1.1M | 36.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 108 | 21,840 | $1.0M | $400,236 | 39.4% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 15 | 11,340 | $960,480 | $396,784 | 41.3% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 15 | 14,640 | $849,120 | $345,186 | 40.7% |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | Office | 2023 | 61 | 568 | $678,382 | $267,253 | 39.4% |
| J1930 | Injection, lanreotide, 1 mg | Office | 2023 | 11 | 5,760 | $921,485 | $252,068 | 27.4% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 217 | 226 | $962,760 | $160,906 | 16.7% |
| G6015 | Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | Office | 2023 | 29 | 431 | $577,971 | $110,612 | 19.1% |
| J9312 | Injection, rituximab, 10 mg | Office | 2023 | 16 | 1,715 | $366,684 | $108,516 | 29.6% |
| J9035 | Injection, bevacizumab, 10 mg | Office | 2023 | 15 | 1,680 | $282,912 | $94,431 | 33.4% |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | Office | 2023 | 52 | 1,080 | $1.2M | $90,205 | 7.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 674 | 1,249 | $197,805 | $77,901 | 39.4% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 68 | 64,500 | $200,595 | $55,690 | 27.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 303 | 565 | $135,068 | $54,387 | 40.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 202 | 549 | $200,934 | $52,506 | 26.1% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 55 | 324 | $348,948 | $43,136 | 12.4% |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | Office | 2023 | 163 | 174 | $144,594 | $34,892 | 24.1% |
| G6013 | Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | Office | 2023 | 17 | 180 | $71,820 | $30,067 | 41.9% |
| 77014 | Ct guidance for insertion of radiation therapy fields | Office | 2023 | 21 | 336 | $137,760 | $29,891 | 21.7% |
| Q5117 | Injection, trastuzumab-anns, biosimilar, (kanjinti), 10 mg | Office | 2023 | 13 | 1,275 | $244,303 | $26,768 | 11.0% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 118 | 125 | $148,500 | $19,732 | 13.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 814 | 2,424 | $82,416 | $18,322 | 22.2% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 781 | 2,125 | $95,625 | $17,501 | 18.3% |
| 80076 | Liver function blood test panel | Office | 2023 | 759 | 2,042 | $85,764 | $16,260 | 19.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 866 | 2,335 | $16,429 | $15,942 | 97.0% |
About Dr. Steven Madden, MD
Dr. Steven Madden, MD is a Hematology & Oncology healthcare provider based in West Columbia, South Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1538198171.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Madden, MD has received a total of $2,667 in payments from pharmaceutical and medical device companies, with $815.72 received in 2024. These payments were reported across 168 transactions from 38 companies. The most common payment nature is "Food and Beverage" ($2,562).
As a Medicare-enrolled provider, Madden has provided services to 35,447 Medicare beneficiaries, totaling 1,046,721 services with total Medicare billing of $15.5M. Data is available for 4 years (2020–2023), covering 393 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location West Columbia, SC
- Active Since 07/03/2006
- Last Updated 03/15/2024
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1538198171
Products in Payments
- IBRANCE (Drug) $156.26
- KEYTRUDA (Biological) $136.24
- AFINITOR (Drug) $92.44
- INJECTAFER (Drug) $86.07
- TASIGNA (Drug) $82.20
- Fabhalta (Drug) $77.27
- REBLOZYL (Biological) $74.38
- SCEMBLIX (Drug) $72.53
- Neulasta (Biological) $67.39
- KYPHON Balloon Kyphoplasty (Device) $60.86
- Perjeta (Biological) $59.04
- KISQALI (Drug) $53.99
- LIBTAYO (Biological) $51.38
- OPDIVO (Biological) $49.42
- KANJINTI (Biological) $46.09
- TECVAYLI (Biological) $45.28
- JADENU (Drug) $43.02
- CALQUENCE (Drug) $42.39
- XGEVA (Biological) $42.38
- MONJUVI (Drug) $41.75
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in West Columbia
Dr. Kavitha Paramanathan, M.d, M.D
Hematology & Oncology — Payments: $6,641
Hematology & Oncology $6,641
Asheesh Lal, M.d, M.D
Hematology & Oncology — Payments: $5,369
Hematology & Oncology $5,369
Dr. Chelsea Stillwell, M.d, M.D
Hematology & Oncology — Payments: $2,936
Hematology & Oncology $2,936
Dr. Scott Graupner, D.o, D.O
Hematology & Oncology — Payments: $2,786
Hematology & Oncology $2,786